Randomised-controlled trials in chronic kidney disease - A call to arms!

International Journal of Clinical Practice

Volumn 66, Issue 10, 2012, Pages 913-915

  Ng, K P ^a   Townend, J N ^a   Ferro, C J ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ALISKIREN; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; SPIRONOLACTONE;

ALBUMINURIA; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG EFFICACY; EDITORIAL; GLOMERULUS FILTRATION RATE; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; IMMUNOGLOBULIN A NEPHROPATHY; INCIDENCE; KIDNEY DYSFUNCTION; KIDNEY FAILURE; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PUBLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; STROKE; UNSPECIFIED SIDE EFFECT;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; GLOMERULONEPHRITIS, IGA; HUMANS;

EID: 84866488109     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2012.03005.x     Document Type: Editorial

References (11)

1. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: S1-266.
2. Chue CD, Townend JN, Steeds RP, Ferro CJ,. Arterial stiffness in chronic kidney disease: causes and consequences. Heart 2010; 96: 817-23.
3. Barratt J, Feehally J,. IgA nephropathy. J Am Soc Nephrol 2005; 16: 2088-97. (Pubitemid 41716440)
4. Fink HA, Ishani A, Taylor BC, et al., Screening for, monitoring, and treatment of chronic kidney disease stages 1 to 3: a systematic review for the U.S. Preventive Services Task Force and for an American College of Physicians Clinical Practice Guideline. Ann Intern Med 2012; 156: 570-81.
5. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T,. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003; 361: 117-24. (Pubitemid 36092015)
6. The Editors. Retraction - Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2009; 374: 1226.
7. Cheng J, Zhang X, Tian J, Li Q, Chen J,. Combination therapy an ACE inhibitor and an angiotensin receptor blocker for IgA nephropathy: a meta-analysis. Int J Clin Pract 2012; 66: 917-23.
8. Strippoli GF, Craig JC, Schena FP,. The number, quality, and coverage of randomized controlled trials in nephrology. J Am Soc Nephrol 2004; 15: 411-9. (Pubitemid 38140782)
9. McMurray JJ, Abraham WT, Dickstein K, Kober L, Massie BM, Krum H,. Aliskiren, ALTITUDE, and the implications for ATMOSPHERE. Eur J Heart Fail 2012; 14: 341-3.
10. Edwards NC, Steeds RP, Stewart PM, Ferro CJ, Townend JN,. Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial. J Am Coll Cardiol 2009; 54: 505-12.
11. Baigent C, Landray MJ, Reith C, et al., The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011; 377: 2181-92.